Cargando…
Targeting glioma stem‐like cell survival and chemoresistance through inhibition of lysine‐specific histone demethylase KDM2B
Glioblastoma (GBM) ranks among the most lethal cancers, with current therapies offering only palliation. Inter‐ and intrapatient heterogeneity is a hallmark of GBM, with epigenetically distinct cancer stem‐like cells (CSCs) at the apex. Targeting GSCs remains a challenging task because of their uniq...
Autores principales: | Staberg, Mikkel, Rasmussen, Rikke Darling, Michaelsen, Signe Regner, Pedersen, Henriette, Jensen, Kamilla Ellermann, Villingshøj, Mette, Skjoth‐Rasmussen, Jane, Brennum, Jannick, Vitting‐Seerup, Kristoffer, Poulsen, Hans Skovgaard, Hamerlik, Petra |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5830623/ https://www.ncbi.nlm.nih.gov/pubmed/29360266 http://dx.doi.org/10.1002/1878-0261.12174 |
Ejemplares similares
-
The impact of bevacizumab treatment on survival and quality of life in newly diagnosed glioblastoma patients
por: Poulsen, Hans Skovgaard, et al.
Publicado: (2014) -
Combined EGFR- and notch inhibition display additive inhibitory effect on glioblastoma cell viability and glioblastoma-induced endothelial cell sprouting in vitro
por: Staberg, Mikkel, et al.
Publicado: (2016) -
VEGF-C sustains VEGFR2 activation under bevacizumab therapy and promotes glioblastoma maintenance
por: Michaelsen, Signe R, et al.
Publicado: (2018) -
Perspective: targeting VEGF-A and YKL-40 in glioblastoma – matter matters
por: Holst, Camilla Bjørnbak, et al.
Publicado: (2021) -
SPT6-driven error-free DNA repair safeguards genomic stability of glioblastoma cancer stem-like cells
por: Obara, Elisabeth Anne Adanma, et al.
Publicado: (2020)